

Verónica González-Calle

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5025915/publications.pdf>

Version: 2024-02-01

42
papers

632
citations

758635

12
h-index

610482

24
g-index

43
all docs

43
docs citations

43
times ranked

1026
citing authors

#	ARTICLE	IF	CITATIONS
1	Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 862-871.	1.2	7
2	Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma. <i>Blood Advances</i> , 2022, 6, 3234-3239.	2.5	18
3	Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem cell transplantation is a prognostic marker of longer progression-free survival and overall survival. <i>British Journal of Haematology</i> , 2022, 198, 278-287.	1.2	6
4	Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors. <i>American Journal of Hematology</i> , 2022, 97, 877-884.	2.0	12
5	MYD88 Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5570.	1.8	14
6	Genetic complexity impacts the clinical outcome of follicular lymphoma patients. <i>Blood Cancer Journal</i> , 2021, 11, 11.	2.8	3
7	Dexamethasone as a partner of isatuximab. <i>Blood</i> , 2021, 137, 1133-1134.	0.6	0
8	Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. <i>Blood Cancer Journal</i> , 2021, 11, 101.	2.8	14
9	Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping. <i>British Journal of Haematology</i> , 2021, 195, 542-551.	1.2	14
10	A New Next-Generation Sequencing Strategy for the Simultaneous Analysis of Mutations and Chromosomal Rearrangements at DNA Level in Acute Myeloid Leukemia Patients. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 60-71.	1.2	11
11	MYC dysregulation in the progression of multiple myeloma. <i>Leukemia</i> , 2020, 34, 322-326.	3.3	108
12	Is there a role for new drugs with alkylating properties in multiple myeloma?. <i>Lancet Haematology</i> , the, 2020, 7, e357-e359.	2.2	2
13	International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). <i>Blood Cancer Journal</i> , 2020, 10, 102.	2.8	126
14	Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 108.	2.8	60
15	Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial. <i>Cancers</i> , 2020, 12, 3615.	1.7	7
16	Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients. <i>Blood Cancer Journal</i> , 2020, 10, 14.	2.8	16
17	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, 503-509.	2.0	11
18	EHA evaluation of the ESMO Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies. <i>ESMO Open</i> , 2020, 5, e000611.	2.0	10

#	ARTICLE	IF	CITATIONS
19	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1885-1893.	0.6	3
20	Prognostic Factors in Systemic Light-Chain Amyloidosis with Cardiac Involvement. Single Center Experience at the University Hospital of Salamanca. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S328.	0.2	0
21	Immunoglobulin gene rearrangement IGHV3-48 is a predictive marker of histological transformation into aggressive lymphoma in follicular lymphomas. <i>Blood Cancer Journal</i> , 2019, 9, 52.	2.8	11
22	Improving the conditioning regimen in multiple myeloma. <i>Lancet Haematology</i> , 2019, 6, e234-e235.	2.2	0
23	Prognostic implications of MRD assessment in multiple myeloma patients: comparison of Next-Generation Sequencing and Next-Generation Flow. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e47.	0.2	2
24	Drug-induced Thrombotic Microangiopathy During Maintenance Treatment in a Patient With Multiple Myeloma. <i>HemaSphere</i> , 2019, 3, e192.	1.2	6
25	Recovery of polyclonal immunoglobulins as a predictor factor of increased progression-free survival and overall survival in patients with multiple myeloma ineligible for ASCT. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e176-e177.	0.2	0
26	Exportin1 E571K mutation is a common finding in patients with classical Hodgkin lymphoma. <i>Hematological Oncology</i> , 2019, 37, 215-218.	0.8	2
27	Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial. <i>Blood</i> , 2019, 134, 694-694.	0.6	4
28	Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDt-ASCT, Consolidation with Krd and Maintenance with Rd. <i>Blood</i> , 2019, 134, 781-781.	0.6	38
29	Evaluation of Revised International Staging System (R-ISS) for transplant-eligible multiple myeloma patients. <i>Annals of Hematology</i> , 2018, 97, 1453-1462.	0.8	26
30	Timing of treatment of smoldering myeloma: early treatment. <i>Blood Advances</i> , 2018, 2, 3045-3049.	2.5	9
31	A safety profile of medications used to treat Waldenström's macroglobulinemia. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 609-621.	1.0	2
32	Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 486-492.e1.	0.2	7
33	Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients. <i>European Journal of Internal Medicine</i> , 2018, 58, 57-63.	1.0	9
34	VDJH Gene Repertoire Analysis in Multiple Myeloma (MM) Patients: Correlation with Clinical Data. <i>Blood</i> , 2018, 132, 4446-4446.	0.6	1
35	Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma. <i>Haematologica</i> , 2017, 102, 922-931.	1.7	34
36	Precision Medicine in Myeloma: Challenges in Defining an Actionable Approach. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 621-630.	0.2	5

#	ARTICLE	IF	CITATIONS
37	Smoldering Multiple Myeloma: Who and When to Treat. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 716-722.	0.2	13
38	Targeted therapy and maintenance in myeloma. <i>British Medical Bulletin</i> , 2017, 122, 163-178.	2.7	0
39	Multiple primary cutaneous plasmacytoma a decade after a nasal solitary extramedullary plasmacytoma: a puzzling case. <i>Clinical Case Reports (discontinued)</i> , 2016, 4, 1096-1100.	0.2	1
40	Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma. <i>Leukemia</i> , 2016, 30, 2026-2031.	3.3	19
41	Evaluation of Revised International Staging System for Transplant-Eligible Multiple Myeloma Patients. <i>Blood</i> , 2016, 128, 3452-3452.	0.6	0
42	Lenalidomide Inhibits Thioredoxin Reductase (TrxR) in Multiple Myeloma (MM) Cells but Direct Inhibition of Trxr and Thioredoxin (Trx) Can Bypass Requirement of Cereblon (CRBN). <i>Blood</i> , 2016, 128, 4482-4482.	0.6	0